This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Han, L. Y. Articles by Sood, A. K. Search for Related Content PubMed PubMed Citation Articles by Han, L. Y. Articles by Sood, A. K.

Antiangiogenic and Antitumor Effects of Src Inhibition in Ovarian Carcinoma

Departments of ¹ Gynecologic Oncology and ² Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston, Texas; ³ Department of Gynecologic Oncology at Cheil General Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea; and ⁴ ARIAD Pharmaceuticals, Cambridge, Massachusetts

Requests for reprints: Anil K. Sood, Department of Gynecologic Oncology, University of Texas M.D. Anderson Cancer Center, 1155 Herman Pressler, CPB6.3244, Unit 1362, Houston, TX 77030. Phone: 713-745-5266; Fax: 713-792-7586; E-mail: asood{at}mdanderson.org.

Src, a nonreceptor tyrosine kinase, is a key mediator for multiple signaling pathways that regulate critical cellular functions and is often aberrantly activated in a number of solid tumors, including ovarian carcinoma. The purpose of this study was to determine the role of activated Src inhibition on tumor growth in an orthotopic murine model of ovarian carcinoma. In vitro studies on HeyA8 and SKOV3ip1 cell lines revealed that Src inhibition by the Src-selective inhibitor, AP23846, occurred within 1 hour and responded in a dose-dependent manner. Furthermore, Src inhibition enhanced the cytotoxicity of docetaxel in both chemosensitive and chemoresistant ovarian cancer cell lines, HeyA8 and HeyA8-MDR, respectively. In vivo, Src inhibition by AP23994, an orally bioavailable analogue of AP23846, significantly decreased tumor burden in HeyA8 (P = 0.02), SKOV3ip1 (P = 0.01), as well as HeyA8-MDR (P < 0.03) relative to the untreated controls. However, the greatest effect on tumor reduction was observed in combination therapy with docetaxel (P < 0.001, P = 0.002, and P = 0.01, for the above models, respectively). Proliferating cell nuclear antigen staining showed that Src inhibition alone (P = 0.02) and in combination with docetaxel (P = 0.007) significantly reduced tumor proliferation. In addition, Src inhibition alone and in combination with docetaxel significantly down-regulated tumoral production of vascular endothelial growth factor and interleukin 8, whereas combination therapy decreased the microvessel density (P = 0.02) and significantly affected vascular permeability (P < 0.05). In summary, Src inhibition with AP23994 has potent antiangiogenic effects and significantly reduces tumor burden in preclinical ovarian cancer models. Thus, Src inhibition may be an attractive therapeutic approach for patients with ovarian carcinoma. (Cancer Res 2006; 66(17): 8633-9)

This article has been cited by other articles:

				Y. Yu, J.-P. Cai, B. Tu, L. Wu, Y. Zhao, X. Liu, L. Li, M. A. McNutt, J. Feng, Q. He, et al. Proliferating Cell Nuclear Antigen Is Protected from Degradation by Forming a Complex with MutT Homolog2 J. Biol. Chem., July 17, 2009; 284(29): 19310 - 19320. [Abstract] [Full Text] [PDF]

				D. L. Wheeler, M. Iida, and E. F. Dunn The Role of Src in Solid Tumors Oncologist, July 1, 2009; 14(7): 667 - 678. [Abstract] [Full Text] [PDF]

				R. Buettner, T. Mesa, A. Vultur, F. Lee, and R. Jove Inhibition of Src Family Kinases with Dasatinib Blocks Migration and Invasion of Human Melanoma Cells Mol. Cancer Res., November 1, 2008; 6(11): 1766 - 1774. [Abstract] [Full Text] [PDF]

				Y. G. Lin, A. Immaneni, W. M. Merritt, L. S. Mangala, S. W. Kim, M. M.K. Shahzad, Y. T.M. Tsang, G. N. Armaiz-Pena, C. Lu, A. A. Kamat, et al. Targeting Aurora Kinase with MK-0457 Inhibits Ovarian Cancer Growth Clin. Cancer Res., September 1, 2008; 14(17): 5437 - 5446. [Abstract] [Full Text] [PDF]

				H. Guan, Z. Zhou, G. E. Gallick, S.-F. Jia, J. Morales, A. K. Sood, S. J. Corey, and E. S. Kleinerman Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma Mol. Cancer Ther., July 1, 2008; 7(7): 1807 - 1816. [Abstract] [Full Text] [PDF]

				W. M. Merritt, Y. G. Lin, W. A. Spannuth, M. S. Fletcher, A. A. Kamat, L. Y. Han, C. N. Landen, N. Jennings, K. De Geest, R. R. Langley, et al. Effect of Interleukin-8 Gene Silencing With Liposome-Encapsulated Small Interfering RNA on Ovarian Cancer Cell Growth J Natl Cancer Inst, March 5, 2008; 100(5): 359 - 372. [Abstract] [Full Text] [PDF]

				C. N. Landen Jr, M. J. Birrer, and A. K. Sood Early Events in the Pathogenesis of Epithelial Ovarian Cancer J. Clin. Oncol., February 20, 2008; 26(6): 995 - 1005. [Abstract] [Full Text] [PDF]

				Y. G. Lin, A. B. Kunnumakkara, A. Nair, W. M. Merritt, L. Y. Han, G. N. Armaiz-Pena, A. A. Kamat, W. A. Spannuth, D. M. Gershenson, S. K. Lutgendorf, et al. Curcumin Inhibits Tumor Growth and Angiogenesis in Ovarian Carcinoma by Targeting the Nuclear Factor-{kappa}B Pathway Clin. Cancer Res., June 1, 2007; 13(11): 3423 - 3430. [Abstract] [Full Text] [PDF]

				C. N. Landen Jr., C. Lu, L. Y. Han, K. T. Coffman, E. Bruckheimer, J. Halder, L. S. Mangala, W. M. Merritt, Y. G. Lin, C. Gao, et al. Efficacy and Antivascular Effects of EphA2 Reduction With an Agonistic Antibody in Ovarian Cancer. J Natl Cancer Inst, November 1, 2006; 98(21): 1558 - 1570. [Abstract] [Full Text] [PDF]